Lymphomas are cancers originating from the lymphoid tissues, and can be divided into two broad categories, Hodgkin lymphoma and non-Hodgkin lymphoma, which can be differentiated by their cellular pathology. Hodgkin lymphoma (HL) is characterized by the presence of neoplastic binucleated B-cells called Reed-Steinberg cells. Exposure to Epstein Barr virus is associated with increased risk of HL. In addition, familial HL has also been described, and first degree relatives of a patient with HL having an increased risk of developing the condition. Non-Hodgkin lymphoma (NHL) is a diverse group of more than 50 types of lymphoma that arise from the lymphoid tissues but do not contain Reed-Steinberg cells, each with distinct morphological, cytogenetic, genetic and clinical features. Exposure to Epstein Barr virus and HIV are associated with increased risk of NHL; the contribution of other lifestyle factors and exposures remains unclear. Families with high rates of NHL have also been described, indicating a hereditary component in some cases. In addition, first degree relatives of patients with NHL have a 1.5-3 fold increased risk of developing the condition, again indicating a genetic component to disease susceptibility. Chronic lymphocytic leukemia (CLL) is considered a subtype of NHL. A 3- to 8.5-fold increased risk of CLL among first-degree relatives of probands has been reported.
Our Tier 1: Hereditary Lymphoma Panel includes sequencing and deletion/duplication analysis of the following 8 genes: CHEK2, KLHDC8B, NPAT, TP53, MLH1, MSH2, MSH6 and PMS2.
NOTE: For patients with a history of lymphoma, cultured skin fibroblasts is the preferred specimen type (2 T-25 flasks). Blood samples can be accepted only if the patient has no history of blood involvement. Please contact the laboratory for more information about specimen requirements.
Any gene in the Tier 1: Hereditary Lymphoma Panel can also be ordered individually. Please contact us directly for cost and CPT code information.